[
    [
        {
            "time": "2018-01-02",
            "original_text": "Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Eucrisa",
                    "Safety",
                    "Kids",
                    "Atopic Dermatitis"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "13 Blue-Chip Stocks With Risks You Need to Watch",
            "features": {
                "keywords": [
                    "Blue-Chip",
                    "Stocks",
                    "Risks",
                    "Watch"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "diverse"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "13 Blue-Chip Stocks With Risks You Need to Watch",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Gilead to Submit NDA for Inflammation Drug Filgotinib in '19",
            "features": {
                "keywords": [
                    "Gilead",
                    "NDA",
                    "Inflammation",
                    "Drug",
                    "Filgotinib"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Gilead to Submit NDA for Inflammation Drug Filgotinib in '19",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]